Korro Bio (KRRO) Income towards Parent Company (2018 - 2026)
Korro Bio (KRRO) posted Income towards Parent Company of -$19.6 million for Q1 2026, down 121.12% on a QoQ basis from $92.9 million in Q4 2025, and up 16.09% year-over-year from -$16.9 million in Q1 2025.
Korro Bio (KRRO) Income towards Parent Company (2018 - 2026) Analysis & Trends
Korro Bio's Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$19.6 million for Q1 2026.
- Quarterly Income towards Parent Company rose 16.09% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.4 million (up 852.88% YoY) and the FY2025 annual result came in at $25.7 million, up 31807.41% from the prior year.
- Income towards Parent Company was -$19.6 million for Q1 2026 at Korro Bio, down from $92.9 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $92.9 million in Q4 2025 and bottomed at -$25.8 million in Q2 2025.
- A 5-year average of -$7.8 million and a median of -$19.6 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company tumbled 511.02% — and 2024, when it jumped 345.03%.
- Korro Bio's Income towards Parent Company stood at $6.2 million in 2022, then tumbled by 511.02% to -$25.4 million in 2023, then soared by 345.03% to $62.3 million in 2024, then soared by 49.12% to $92.9 million in 2025, then sank by 121.12% to -$19.6 million in 2026.
- Business Quant data shows KRRO's Income towards Parent Company at -$19.6 million in Q1 2026, $92.9 million in Q4 2025, and -$18.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Korro Bio | 123.06 Mn | 9.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | 92.90 Mn |
| Sep 30, 2025 | -18.06 Mn |
| Jun 30, 2025 | -25.77 Mn |
| Mar 31, 2025 | -23.39 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Sep 30, 2024 | -21.00 Mn |
| Jun 30, 2024 | -21.83 Mn |
| Mar 31, 2024 | -19.56 Mn |
| Dec 31, 2023 | -25.43 Mn |
| Sep 30, 2023 | -18.49 Mn |
| Jun 30, 2023 | -17.65 Mn |
| Mar 31, 2023 | -19.61 Mn |
| Dec 31, 2022 | 6.19 Mn |
| Sep 30, 2022 | -19.55 Mn |
| Jun 30, 2022 | -21.29 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -21.50 Mn |
| Sep 30, 2021 | -25.16 Mn |
| Jun 30, 2021 | -17.66 Mn |